London: Pharmaceutical company GlaxoSmithKline says its net profit rose 50 per cent in the third quarter to £808 million ($986 million, Dh3.9 billion) thanks in part to strong sales of its vaccine products. The London-based company said on Wednesday that revenue grew 23 per cent to £7.54 billion. CEO Andrew Witty cited “the sustained progress we have made over the course of 2016 to deliver sales growth of new products, maintain effective cost control and execute on our restructuring and integration plans.”
GSK saw good demand for its flu and meningitis vaccines, particularly in the US. It’s trying to increase its range of products as some of its older treatments lose patent protection.
